.Attributes Medicine, Posted online: 30 July 2024 doi:10.1038/ d41591-024-00054-wThe antitoxin-- medicine conjugate (ADC) tisotumab vedotin resulted in enhanced progression-free and general survival, triggering FDA approval and a brand-new treatment alternative for clients.